(Reuters) – AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance, AstraZeneca said.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich)
